Butorphanol

Butorphanol is a morphinan-type synthetic agonist–antagonist opioid analgesic developed by Bristol-Myers.[1][2][3][4][5] Butorphanol is most closely structurally related to levorphanol. Butorphanol is available as the tartrate salt in injectable, tablet, and intranasal spray formulations. The tablet form is only used in dogs, cats and horses due to low bioavailability in humans.

Butorphanol
Clinical data
Trade namesStadol, others
Other namesBC 2627
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa682667
Pregnancy
category
  • C/D (United States)
Routes of
administration		IV, intranasal, oral
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityNasal: 60-70%, Sublingual/Buccal 25%-35%. PO < OR= to 10%. * Try to use IN route best used out of the hospital setting or both choices. has longer duration of action ~ 5 hours. IV 2-4 hours. Avoid oral route unless stronger advised by a physician.
MetabolismLiver hydroxylated & glucuronidated
Elimination half-life4-7 hours
ExcretionKidney, 75%
Biliary, 11-14%
Fecal, 15%
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.050.717
Chemical and physical data
FormulaC21H29NO2
Molar mass327.468 g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

It was patented in 1971 and approved for medical use in 1979.[6]

Medical uses

The most common indication for butorphanol is management of migraine using the intranasal spray formulation. It may also be used parenterally for management of moderate-to-severe pain, as a supplement for balanced general anesthesia, and management of pain during labor. Butorphanol is also quite effective at reducing post-operative shivering (owing to its Kappa agonist activity). Butorphanol is more effective in reducing pain in women than in men.[7]

Pharmacology

Butorphanol exhibits partial agonist and antagonist activity at the μ-opioid receptor, as well as partial agonist activity at the κ-opioid receptor (Ki = 2.5 nM; EC50 = 57 nM; Emax = 57%).[7][8] Stimulation of these receptors on central nervous system neurons causes an intracellular inhibition of adenylate cyclase, closing of influx membrane calcium channels, and opening of membrane potassium channels. This leads to hyperpolarization of the cell membrane potential and suppression of action potential transmission of ascending pain pathways. Because of its κ-agonist activity, at analgesic doses butorphanol increases pulmonary arterial pressure and cardiac work. Additionally, κ-agonism can cause dysphoria at therapeutic or supertherapeutic doses; this gives butorphanol a lower potential for abuse than other opioid drugs.[9]

Side effects

As with other opioid analgesics, central nervous system effects (such as sedation, confusion, and dizziness) are considerations with butorphanol. Nausea and vomiting are common. Less common are the gastrointestinal effects of other opioids (mostly constipation). Another side effect experienced by people taking the medication is increased perspiration.

Society and culture

Name

Within the INN, USAN, BAN, and AAN naming systems this drug is known as butorphanol, while within JAN it is named torbugesic.[3][4][5] As the tartrate salt, butorphanol is known as butorphanol tartrate (USAN, BAN).[3][4][5]

Its tradename Stadol was recently discontinued by the manufacturer. It is now only available in its generic formulations manufactured by Apotex, Mylan, Novex and Ben Venue Laboratories.

Availability

Butorphanol is available in the U.S. as a generic drug; it is available in various nations under one of any number of trade names, including Moradol and Beforal (Brand name Stadol no longer available in the US); veterinary trade names include Butorphic, Dolorex, Morphasol, Torbugesic, and Torbutrol.

Legality

Butorphanol is listed under the Single Convention on Narcotic Drugs 1961 and in the United States is a Schedule IV Narcotic controlled substance with a DEA ACSCN of 9720; being in Schedule IV it is not subject to annual aggregate manufacturing quotas. The free base conversion ratio of the hydrochloride is 0.69.[10] Butorphanol was originally in Schedule II and at one point it was decontrolled.

Veterinary use

In veterinary anesthesia, butorphanol (trade name: Torbugesic) is widely used as a sedative and analgesic in dogs, cats and horses. For sedation, it may be combined with tranquilizers such as alpha-2 agonists (medetomidine), benzodiazepines, or acepromazine in dogs, cats and exotic animals. It is frequently combined with xylazine or detomidine in horses.[11]

Butorphanol is frequently used for post-operative and accident-related pain in small mammals such as dogs, cats, ferrets, coatis, raccoons, mongooses, various marsupials, some rodents and perhaps some larger birds, both in the operating suite and as a regular prescription medication for home use, for management of moderate to severe pain.

Although butorphanol is commonly used for pain relief in reptiles, no studies (as of 2014) have conclusively shown that is an effective analgesic in reptiles.[12]

Use in horses

Butorphanol is a commonly used narcotic for pain relief in horses. It is administered either IM or IV, with its analgesic properties beginning to take effect about 15 minutes after injection and lasting 4 hours. It is also commonly paired with sedatives, such as xylazine and detomidine, to make the horse easier to handle during veterinary procedures.

Side effects specific to horses include sedation, CNS excitement (displayed by head pressing or tossing). Overdosing may result in seizures, falling, salivation, constipation, and muscle twitching. If an overdose occurs, a narcotic antagonist, such as naloxone, may be given. Caution should be used if butorphanol is administered in addition to other narcotics, sedatives, depressants, or antihistamines as it will cause an additive effect.

Butorphanol can cross the placenta, and it will be present in the milk of lactating mares who are given the drug.

The drug is also prohibited for use in competition by most equestrian organizations, including the FEI, which considers it a class A drug.

gollark: Idea: EWO bots.
gollark: Yeees.
gollark: Oh no, my U+202E player died.
gollark: Hey, maybe if there was some sort of alternating checkerboard pattern on the floor it would look like you're moving more.
gollark: Also balance.

See also

Notes
  1. US Patent US Patent 3819635 14-hydroxymorphinan derivatives
  2. US 3775414 Process for the preparation of 14-hydroxymorphinan derivatives
  3. Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 200–. ISBN 978-1-4757-2085-3.
  4. Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 154–. ISBN 978-3-88763-075-1.
  5. Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 58–. ISBN 978-94-011-4439-1.
  6. Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 529. ISBN 978-3-527-60749-5.
  7. Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, Levine JD (November 1999). "The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain". Pain. 83 (2): 339–45. doi:10.1016/S0304-3959(99)00119-0. PMID 10534607.
  8. Gharagozlou P, Hashemi E, DeLorey TM, Clark JD, Lameh J (January 2006). "Pharmacological profiles of opioid ligands at kappa opioid receptors". BMC Pharmacology. 6 (1): 3. doi:10.1186/1471-2210-6-3. PMC 1403760. PMID 16433932.
  9. "Critical Review of Butorphanol" (PDF). 34th ECDD 2006/4.1. World Health Organization.
  10. "Conversion Factors for Controlled Substances". DEA Diversion Control Division. United States Drug Enforcement Administration.
  11. Compendium of Data sheets for Animal Medicines. 2005. National Office of Animal Health. October 2004. ISBN 978-0-9548037-0-4.
  12. Sladky KK (2014). "Chapter 18: Analgesia". In Mader DR, Divers SJ (eds.). Current therapy in reptile medicine & surgery. Elsevier Health Sciences. pp. 217–229. ISBN 978-0-323-24293-6.

References
  • Katzung BG (2001). Basic & Clinical Pharmacology (8th ed.). New York: McGraw-Hill. ISBN 978-0-8385-0598-4.
  • Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, DiPiro JT (2005). Pharmacotherapy: A Pathophysiologic Approach (6th ed.). New York: McGraw-Hill. ISBN 0-07-141613-7.
  • Forney BC (2007). Equine Medications (Revised ed.). Lexington, Kentucky: Blood Horse Publications.
  • The Merck Manual of Veterinary Medicine. 2004.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.